A Mononuclear Copper(II) Complex Containing Benzimidazole and Pyridyl Ligands: Synthesis, Characterization, and Antiproliferative Activity against Human Cancer Cells

In this study, first we determined toxic doses of this complex on NIH/3T3 normal fibroblast cells, SPC212 mesothelioma and ascertained anti-proliferative, apoptotic and morphological effects of these newly synthesized compounds on DU145 prostate cancer cells through cytotoxic and microscopic methods. A novel Copper(II)/1-(4-(trifluoromethyl)benzyl)-1H-benzimidazole/2,2’-bipyridyl complex, was synthesized, and mainly characterized by single crystal x-ray diffraction analysis. Anti-proliferative effect of copper(II) complex was gauged by MTT. Its morphological effect was examined by microscope analysis. Besides, immunocytochemistry of Bax, a pro-apoptotic protein and PCNA, a proliferation marker protein was performed. As a result, the inhibitory effect of newly synthesized substance was superior to the chemicals from which it was synthesized. Its IC50s were 37.0, 21.1 and 10.0 µM for 24, 48 and 72 h-treatments, respectively. In microscopy, we observed apoptotic hallmarks like nuclear condensation, cellular shrinkage and membrane blebbings. In immunochemistry, increased Bax and decreased PCNA were apparent. Copper(II) complex with its relatively low IC50 can also be tested on other cancer and normal cell lines.
Source: Arabian Journal of Chemistry - Category: Chemistry Source Type: research